Evidence map›Paper›PMID 32993558›Full record

ArticleBMC cancer2020

Reconstruction of lncRNA-miRNA-mRNA network based on competitive endogenous RNA reveals functional lncRNAs in skin cutaneous melanoma.

Junyou Zhu, Jin Deng, Lijun Zhang, Jingling Zhao, Fei Zhou, Ning Liu, Ruizhao Cai, Jun Wu, Bin Shu, Shaohai Qi

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Junyou ZhuDepartment of Burn, The First Affiliated Hospital, Sun yat-sen University, Guangzhou, Guangdong, 510080, People's Republic of China.
Jin DengDepartment of Radiation Oncology, Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, 510095, People's Republic of China.
Lijun ZhangDepartment of Burn, The First Affiliated Hospital, Sun yat-sen University, Guangzhou, Guangdong, 510080, People's Republic of China.
Jingling ZhaoDepartment of Burn, The First Affiliated Hospital, Sun yat-sen University, Guangzhou, Guangdong, 510080, People's Republic of China.
Fei ZhouDepartment of Burn, The First Affiliated Hospital, Sun yat-sen University, Guangzhou, Guangdong, 510080, People's Republic of China.
Ning LiuDepartment of Burn, The First Affiliated Hospital, Sun yat-sen University, Guangzhou, Guangdong, 510080, People's Republic of China.
Ruizhao CaiDepartment of Burn, The First Affiliated Hospital, Sun yat-sen University, Guangzhou, Guangdong, 510080, People's Republic of China.
Jun WuDepartment of Burn, The First Affiliated Hospital, Sun yat-sen University, Guangzhou, Guangdong, 510080, People's Republic of China.
Bin ShuDepartment of Burn, The First Affiliated Hospital, Sun yat-sen University, Guangzhou, Guangdong, 510080, People's Republic of China. shubin29@sina.com.
Shaohai QiDepartment of Burn, The First Affiliated Hospital, Sun yat-sen University, Guangzhou, Guangdong, 510080, People's Republic of China. qishh@mail.sysu.edu.cn.
The First Affiliated Hospital, Sun Yat-sen University · CNSun Yat-sen University · CNGuangzhou Medical University · CN

Funding

Natural Science Foundation of Guangdong Province 2017A030313619Science and Technology Program of Guangzhou 201704020165
6 · The paper itself

Abstract

backgroundHuman skin cutaneous melanoma is the most common and dangerous skin tumour, but its pathogenesis is still unclear. Although some progress has been made in genetic research, no molecular indicators related to the treatment and prognosis of melanoma have been found. In various diseases, dysregulation of lncRNA is common, but its role has not been fully elucidated. In recent years, the birth of the "competitive endogenous RNA" theory has promoted our understanding of lncRNAs.

methodsTo identify the key lncRNAs in melanoma, we reconstructed a global triple network based on the "competitive endogenous RNA" theory. Gene Ontology and KEGG pathway analysis were performed using DAVID (Database for Annotation, Visualization, and Integration Discovery). Our findings were validated through qRT-PCR assays. Moreover, to determine whether the identified hub gene signature is capable of predicting the survival of cutaneous melanoma patients, a multivariate Cox regression model was performed.

resultsAccording to the "competitive endogenous RNA" theory, 898 differentially expressed mRNAs, 53 differentially expressed lncRNAs and 16 differentially expressed miRNAs were selected to reconstruct the competitive endogenous RNA network. MALAT1, LINC00943, and LINC00261 were selected as hub genes and are responsible for the tumorigenesis and prognosis of cutaneous melanoma.

conclusionsMALAT1, LINC00943, and LINC00261 may be closely related to tumorigenesis in cutaneous melanoma. In addition, MALAT1 and LINC00943 may be independent risk factors for the prognosis of patients with this condition and might become predictive molecules for the long-term treatment of melanoma and potential therapeutic targets.

Indexed as

CarcinogenesisCutaneous Malignant MelanomaFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansKaplan-Meier EstimateMaleMelanomaMicroRNAsPrognosisRNA, Long NoncodingRNA, MessengerSkin NeoplasmsMALAT1 long non-coding RNA, humanMicroRNAsRNA, Long NoncodingRNA, MessengerCompetitive endogenous RNAHuman skin cutaneous melanomaLINC00261LINC00943lncRNAMALAT1miRNA

Identifiers

PMID32993558
PMCPMC7523354
OpenAlexW3090572346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.